Back |
home / stock / addxf / addxf message board
Subject | By | Source | When |
---|---|---|---|
New Edison report out (after CEO hire): | tykundegex | investorshub | 08/17/2011 10:20:35 AM |
Addex H1 results | tykundegex | investorshub | 08/15/2011 10:07:04 AM |
Coverage of Addex by Edison from June | tykundegex | investorshub | 08/15/2011 10:04:35 AM |
Corporate Presentation from Aug 5 | tykundegex | investorshub | 08/15/2011 9:55:19 AM |
News: Addex Pharmaceuticals Appoints Dr Bharatt Chowrira as CEO | tykundegex | investorshub | 08/15/2011 8:46:29 AM |
Board just created today. I have been | tykundegex | investorshub | 07/14/2011 10:49:12 AM |
Article in Geneva-based Le Temps newspaper about restructuring: | tykundegex | investorshub | 07/14/2011 10:45:20 AM |
Selling non-executive director: 5000 on 4 July | tykundegex | investorshub | 07/14/2011 10:25:14 AM |
Selling by non-executive director: 5000 on 11 July | tykundegex | investorshub | 07/14/2011 10:21:24 AM |
News, Short Squeeze, Breakout and More Instantly...
Addex Pharms Ltd Ord Company Name:
ADDXF Stock Symbol:
OTCMKTS Market:
Addex Pharms Ltd Ord Website:
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological...
Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of T...
● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024 . Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutic...